PXVX0200

BIOLOGICAL3 trials

Sponsors

Bavarian Nordic

Conditions

Cholera

Phase 1

Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200

CompletedNCT01585181

Bavarian NordicCholera

Start: 2012-04-30End: 2013-01-31Updated: 2023-06-27

Phase 3

Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera

CompletedNCT01895855

Bavarian NordicCholera

Start: 2013-09-30End: 2014-11-30Updated: 2023-06-28

A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults

CompletedNCT02100631

Bavarian NordicCholera

Start: 2014-05-31End: 2015-06-30Updated: 2023-06-28

Related Papers

Immune responses to O-specific polysaccharide (OSP) in North American adults infected with Vibrio cholerae O1 Inaba

PLoS neglected tropical diseases2019-11-1914 citations

Age-related immunogenicity and reactogenicity of live oral cholera vaccine CVD 103-HgR in a randomized, controlled clinical trial

Vaccine2019-02-1312 citations

Lipopolysaccharide-specific memory B cell responses to an attenuated live cholera vaccine are associated with protection against Vibrio cholerae infection

Vaccine2018-04-1128 citations

Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers

PLoS neglected tropical diseases2018-04-0636 citations

Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With<i>Vibrio cholerae</i>O1 El Tor

Clinical Infectious Diseases2016-03-21186 citations

Safety and Immunogenicity of Single-Dose Live Oral Cholera Vaccine Strain CVD 103-HgR, Prepared from New Master and Working Cell Banks

Clinical and Vaccine Immunology2013-10-3050 citations